CATALYST PHARMACEUTICALS, INC.
DelistedCIK 1369568fmd_1RF4DJG9Y2GJ46NE4DHE174N6BManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 04, 2002 to Mar 31, 2026, 72 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 1 | 102 | 119 | 141 | 214 | 398 | 492 | 589 |
| Cost of revenue | – | – | – | 15 | 17 | 22 | 34 | 52 | 69 | 87 |
| Gross profit | – | – | – | 88 | 102 | 119 | 180 | 346 | 423 | 502 |
| Research and development | 11 | 11 | 20 | 19 | 16 | 17 | 20 | 93 | 13 | 13 |
| Selling, general and administrative | – | – | 16 | 37 | 44 | 50 | 57 | 134 | 178 | 194 |
| Total operating expenses | 19 | 19 | 36 | – | – | – | 77 | 227 | 190 | 206 |
| Operating income | (19) | (19) | (35) | 32 | 41 | 52 | 102 | 87 | 195 | 258 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 0 | 0 | 1 | 2 | 1 | 0 | 3 | 8 | 21 | 26 |
| Income before taxes | (18) | (18) | (34) | 33 | 42 | 53 | 105 | 95 | 216 | 284 |
| Income tax expense | 0 | 0 | 0 | 2 | (33) | 13 | 22 | 23 | 52 | 69 |
| Net income from continuing operations | (18) | (18) | (34) | 32 | 75 | 39 | 83 | 71 | 164 | 214 |
| Net income | (18) | (18) | (34) | 32 | 75 | 39 | 83 | 71 | 164 | 214 |